The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211

被引：0
|
作者：
Robesti, D. [1 ]
Nocera, L. [1 ]
Belladelli, F. [1 ]
Schultz, J. G. [2 ]
Fallara, G. [1 ]
Marandino, L. [3 ]
Raggi, D. [3 ]
Montorsi, F. [1 ]
Necchi, A. [3 ]
Martini, A. [4 ]
机构：
[1] IRCCS Osped San Raffaele, Urol Res Inst, Dept Urol, Dept Expt Oncol, Milan, Italy
[2] NCI, NIH, Bethesda, MD USA
[3] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy
[4] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0535
引用
收藏
页码：S763 / S764
页数：2
相关论文
共 32 条
  • [1] THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMVIGOR210 AND IMVIGOR211
    Robesti, Daniele
    Nocera, Luigi
    Belladelli, Federico
    Schultz, Julianne G.
    Fallara, Giuseppe
    Marandino, Laura
    Raggi, Daniele
    Montorsi, Francesco
    Necchi, Andrea
    Martini, Alberto
    JOURNAL OF UROLOGY, 2023, 209 : E244 - E245
  • [2] The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials
    Robesti, Daniele
    Nocera, Luigi
    Belladelli, Federico
    Schultz, Julianne G. G.
    Fallara, Giuseppe
    Marandino, Laura
    Raggi, Daniele
    Montorsi, Francesco
    Msaouel, Pavlos
    Necchi, Andrea
    Martini, Alberto
    BJU INTERNATIONAL, 2024, 133 (02) : 158 - 168
  • [3] Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211
    Fallara, Giuseppe
    Belladelli, Federico
    Robesti, Daniele
    Malavaud, Bernard
    Tholomier, Come
    Mokkapati, Sharada
    Montorsi, Francesco
    Dinney, Colin P.
    Msaouel, Pavlos
    Martini, Alberto
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03) : 188e9 - 188e17
  • [4] Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
    Sotelo, M.
    Alonso-Gordoa, T.
    Gajate, P.
    Gallardo, E.
    Morales-Barrera, R.
    Perez-Gracia, J. L.
    Puente, J.
    Sanchez, P.
    Castellano, D.
    Duran, I.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 882 - 891
  • [5] Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
    M. Sotelo
    T. Alonso-Gordoa
    P. Gajate
    E. Gallardo
    R. Morales-Barrera
    J. L. Pérez-Gracia
    J. Puente
    P. Sánchez
    D. Castellano
    I. Durán
    Clinical and Translational Oncology, 2021, 23 : 882 - 891
  • [6] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    von Amsberg, G.
    Balar, A. V.
    Dreicer, R.
    Loriot, Y.
    Perez-Gracia, J. L.
    Hoffman-Censits, J. H.
    Petrylak, D. P.
    van der Heijden, M. S.
    Shen, X.
    Ding, B.
    Rosenberg, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 106 - 106
  • [7] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Shen, Xiaodong
    Ding, Beiying
    Ramirez-Montagut, Teresa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
    Necchi, A.
    Joseph, R. W.
    Loriot, Y.
    Hoffman-Censits, J.
    Perez-Gracia, J. L.
    Petrylak, D. P.
    Derleth, C. L.
    Tayama, D.
    Zhu, Q.
    Ding, B.
    Kaiser, C.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3044 - 3050
  • [9] Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
    Loriot, Y.
    Rosenberg, J. E.
    Powles, T. B.
    Necchi, A.
    Hussain, S.
    Morales, R.
    Retz, M.
    Niegisch, G.
    Duran, I.
    Theodore, C.
    Perez-Gracia, J. L.
    Grande Pulido, E.
    Thastrom, A.
    Danner, B.
    Mariathasan, S.
    Abidoye, O.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Joseph, Richard W.
    Loriot, Yohann
    Luis Perez-Gracia, Jose
    Dreicer, Robert
    Petrylak, Daniel P.
    van der Heijden, Michiel S.
    Hoffman-Censits, Jean
    Shen, Xiadong
    Fear, Simon
    Pavlova, Julie
    Rosenberg, Jonathan E.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1039 - E1039
1234